Teva Pharmaceutical Industries Ltd
—- Market cap
- —
- Debt
- —
- Cash
- —
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $26.51B · View financials
Decision snapshot: Teva Pharmaceutical Industries Ltd stock price vs LH: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at LH's multiple
Needs EPS (TTM), LH P/E.
Implied fair value · at Teva Pharmaceutical Industries Ltd's multiple
Needs Teva Pharmaceutical Industries Ltd P/E.
Engine logicTeva Pharmaceutical Industries Ltdvalued onLH’smultiple
Metric by metric
Snapshot Sep 4, 4:00 PM ET
Where each company leads, and how wide the gap is.
Higher is better
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: Teva Pharmaceutical Industries Ltd Latest annual filing · LH FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 83% equity / 17% debt · EV / Revenue 2.26x · EV / EBITDA 17.36x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
TEVA PHARMACEUTICAL INDUSTRIES LTD · implied price per share
Reporting currency could not be verified.
LABCORP HOLDINGS INC. · implied price per share
Bear
$113.84
Base
$138.62
Bull
$182.73
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Teva Pharmaceutical Industries Ltd · not enough data.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
—
0.65x
Net debt / EBITDA
Leverage against operating earnings
—
2.78x
Cash and equivalents
Liquid reserves on the balance sheet
—
$532.30M
Total debt
Interest-bearing obligations outstanding
—
$5.58B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
THERMO FISHER SCIENTIFIC INC.
Teva Pharmaceutical Industries Ltd vs TMO
DANAHER CORP /DE/
Teva Pharmaceutical Industries Ltd vs DHR
QUEST DIAGNOSTICS INC
Teva Pharmaceutical Industries Ltd vs DGX
WEST PHARMACEUTICAL SERVICES INC
Teva Pharmaceutical Industries Ltd vs WST
BAXTER INTERNATIONAL INC
Teva Pharmaceutical Industries Ltd vs BAX
MCKESSON CORP
Teva Pharmaceutical Industries Ltd vs MCK
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.